GlassScriptPhysician profile
Bianca M Previdi
NPI 1902060486
$28,172.59
in general payments reported to CMS, 2019-2025
14 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $247 · 2021: $286 · 2022: $596 · 2023: $1,384 · 2024: $940 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $3,277 · Travel and Lodging: $84.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,175.00 |
| Food and Beverage | $3,276.81 |
| Travel and Lodging | $84.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24,994.87 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $712.92 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $500.43 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $411.57 | 2022-2025 | Auvelity |
| Alkermes, INC. | $346.67 | 2019-2024 | Aristada, Lybalvi, Vivitrol |
| Sunovion Pharmaceuticals INC. | $319.35 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $293.28 | 2019-2025 | |
| Allergan, INC. | $152.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.26 | 2019-2025 | Trintellix |
| Indivior INC. | $86.33 | 2022-2024 | Sublocade |
| Janssen Pharmaceuticals, INC | $84.56 | 2019-2025 | Invega Sustenna |
| Braeburn INC. | $78.78 | 2024-2025 | Brixadi |
| Avanir Pharmaceuticals, INC. | $59.33 | 2019 | |
| Lundbeck LLC | $18.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bianca Previdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.